Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERSE: Avacopan Added to SOC in AAV With Severe Kidney Involvement
NCT07373262Phase 3Not yet recruiting
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Mar 2026
- Primary completion
- Mar 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of avacopan in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Centre hospitalier universitaire de Toulouse. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
avacopan
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT07373262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07373262.